Another CRL for Third Party Manufacturing Issues — This Time for Merck-Daiichi

Merck and Daiichi Sankyo’s non-small cell lung cancer drug suffered a setback with the companies’ receipt of an FDA complete response letter (CRL) identifying third party manufacturer inspection issues as the reason for rejecting the drug application.
Source: Drug Industry Daily

Leave a Comment





This site uses Akismet to reduce spam. Learn how your comment data is processed.